Talphera, Inc.

As of November 8, 2023, Talphera, Inc. is considered overvalued due to its negative financial metrics, including a negative P/E ratio, a Price to Book Value of 1.87, a ROCE of -206.75%, and a year-to-date stock return of -16.05%, significantly underperforming the S&P 500.

As of June 4, 2025, Talphera, Inc. has a mildly bearish trend due to conflicting indicators, with bullish signals from MACD and KST on some time frames but bearish moving averages and Bollinger Bands overall.

As of March 2022, the management team of Talphera, Inc. includes Mr. Adrian Adams (Independent Chairman), Mr. Vincent Angotti (CEO), Dr. Pamela Palmer (Co-Founder and CMO), and several independent directors: Dr. Richard Afable, Mr. Mark Edwards, Dr. Stephen Hoffman, Mr. Howard Rosen, and Mr. Mark Wan. This team provides executive leadership and governance for the company.

Talphera, Inc. is a micro-cap specialty pharmaceutical company focused on developing therapies for acute pain. As of March 2025, it reported net sales of $0 million and a net loss of $3 million, with a market cap of $9.74 million.

As of Jun 18, Talphera, Inc. has a market capitalization of 9.74 million, with net sales of 0.03 million and a net profit of -11.72 million over the latest four quarters. The company's shareholder's funds are 8.00 million, and total assets are 18.24 million.